🔹 RBRK — Rubrik Rubrik reported Q2 FY2027 revenue of $427.3M (+38% YoY), driven by strong demand for cloud data security, cyber resilience and AI-related security solutions. Subscription ARR grew 33% YoY to $1.66B, while the company raised its FY2027 outlook. Key Highlights - 📈 Q2 FY2027 revenue: $427.3M (+38% YoY) - ☁️ Subscription ARR: $1.66B (+33% YoY) - 🛡️ Strong demand for cloud data security and cyber resilience - 🚀 Raised FY2027 outlook - 💰 Improving cash-flow margins remain a key catalyst Resistance: $115.40, $117.40 Support: $111.50, $109.50 For Detailed Analysis: https://t.me/c/2454754655/8421 💡 Why It Matters Rubrik’s continued subscription growth, strong demand for cyber resilience and improving cash-flow profile support its growth outlook. Execution and valuation remain key factors to watch. 🔹 DXC — DXC Technology DXC Technology is focusing on business transformation, AI-enabled IT services and operational efficiency. Q1 FY2027 revenue was approximately $3.0B, down 5% YoY, while a potential $2.4B sale of its insurance software and services division could support portfolio simplification. Key Highlights - 💻 Q1 FY2027 revenue: ~$3.0B (-5% YoY) - 🤖 Focus on AI-enabled IT services and business transformation - 💼 Potential $2.4B insurance software and services sale - 📊 Strong recent trading volume - 🔄 Asset sales could support portfolio simplification Resistance: $14.50, $15.00 Support: $13.50, $12.30 For Detailed Analysis: https://t.me/c/2454754655/10461 💡 Why It Matters DXC’s AI and IT-services initiatives provide growth opportunities, while potential asset sales could simplify the business. Declining revenue and profitability remain key risks. 🔹 VSTM — Verastem Oncology Verastem Oncology combines an FDA-approved ovarian cancer treatment with a pipeline targeting KRAS-driven cancers. VS-7375 has shown encouraging early clinical activity, with Phase 3 preparations and TARGET-D enrollment completion targeted by year-end 2026. Key Highlights - 🧬 VS-7375 targets KRAS-driven cancers - 🏥 FDA-approved ovarian cancer treatment provides a commercial foundation - 📊 Phase 3 preparations progressing - 🎯 TARGET-D enrollment completion targeted by year-end 2026 - 🚀 RAMP 301 results expected in mid-2027 - ⚠️ Potential dilution and clinical-trial risks remain For Detailed Analysis: https://t.me/c/2454754655/10392 💡 Why It Matters Verastem offers significant potential through its clinical pipeline and KRAS-focused strategy, but the opportunity remains highly dependent on clinical execution, regulatory progress and funding. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified